Trellus Health Secures Six-Month Extension with Johnson & Johnson for IBD Digital Platform
Key Insights
Trellus Health (search) received a six-month contract extension from Johnson & Johnson to continue providing its Trellus Elevate (search) digital platform for inflammatory bowel disease (search) patients through mid-2026.
The extension was granted based on achievement of key engagement and satisfaction metrics during the initial pilot phase, with J&J (search) expanding patient access channels in response to positive performance.
The company is simultaneously scaling its TrialSet (search) platform across multiple clinical trials with major pharmaceutical partners including Takeda (search) and Sanofi through leading CRO partnerships.
Trellus Health (search) plc announced a six-month contract extension with Johnson & Johnson Health Care Systems to continue providing its Trellus Elevate (search) digital platform for patients with moderate to severely active inflammatory bowel disease (search) who are prescribed J&J (search) therapies. The extension, running through mid-2026, maintains the same economic terms including a fixed monthly management fee.
The collaboration, originally signed in January 2025, was extended based on achievement of key engagement and satisfaction metrics during the initial pilot phase. Johnson & Johnson demonstrated increased confidence in the program by broadening patient access to enrollment channels beyond the initial pilot funnel in mid-January 2026.
Platform Performance and Clinical Impact
Trellus Elevate (search) integrates data analytics with personalized, scientifically proven resilience programs to help patients navigate the emotional and physical challenges of chronic conditions while maintaining treatment adherence. The platform's clinical effectiveness has been demonstrated through significant healthcare utilization reductions among IBD (search) patients, with over 90% fewer hospitalizations and a reduction of over 70% in emergency room visits.
The digital platform combines Trellus Health (search)'s proprietary resilience-based methodology with technology tools and expert coaching to deliver whole-person condition management. The company initially focuses on chronic gastrointestinal conditions with high mental health burdens, particularly inflammatory bowel disease (search).
Expanding Clinical Trial Operations
Trellus Health (search) continues advancing its TrialSet (search) vertical across multiple pharmaceutical partnerships. The company is deploying TrialSet with ICON plc for an ongoing mid-stage immunology and inflammation clinical trial sponsored by Takeda (search). Additionally, Trellus is implementing TrialSet with PSI Inc. (search) across two late-stage immunology and inflammation clinical trials sponsored by Sanofi, with deployment beginning mid-Q2 at agreed-upon sites.
"The extension of our collaboration with J&J (search) represents further external validation of our platform and the engagement outcomes achieved during the pilot phase," said Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health (search). "Together with the rollout of TrialSet (search) with leading CRO partners, Trellus Health operates across the full programme lifecycle, from clinical trials through commercial deployment, using our proprietary resilience methodology to support engagement and programme success."
Financial Position and Growth Strategy
The company expects revenue for 2025 to reach approximately $545,000 and has reduced monthly cash burn to approximately $400,000 by late 2025, down from $440,000 in October 2025. This reduction was partially offset by recurring monthly management fees generated during the second half of the year.
Trellus Health (search) secured a £5 million convertible facility with Alumni Capital LLC (search), approved by shareholders on January 20, 2026. The net proceeds from the First Tranche Notes and Second Tranche Notes (£737,500 in gross principal) are expected to extend the company's cash runway into late Q1 2026. Directors continue discussions regarding additional funding sources to further extend operational runway.
The Board focuses on accelerating commercial momentum through strategic partnerships, deepening pharmaceutical collaborations, and scaling TrialSet (search) across additional programs and sponsors. Management believes the contract extension combined with ongoing CRO implementations positions the company to build increasing recurring revenue visibility through 2026.
Scientific Foundation and Leadership
Trellus Health (search) was founded by Icahn School of Medicine at Mount Sinai faculty members Dr. Marla C. Dubinsky and Dr. Laurie Keefer, both recognized experts in treating the physical and emotional impacts of IBD (search) with a combined 50 years of whole-person healthcare innovation experience. Both founders maintain financial interests in the company and continue their involvement in its scientific direction.